Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The UK Collaborative HIV Cohort Study

Next Previous
Trial Profile

The UK Collaborative HIV Cohort Study

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darunavir (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Antiretrovirals; Atazanavir; Lopinavir
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms UK CHIC

    • Most Recent Events

    • 16 Feb 2022 Results from this and other study compared virological suppression and all-cause mortality between different InSTI- and non-InSTI-based regimens among PWH starting ART in Europe and North America, presented at the 29th Conference on Retroviruses and Opportunistic Infections
    • 20 Feb 2017 Results of subgroup analysis assessing kidney function in patients who switched from atazanavir or lopinavir to darunavir published in the AIDS.
    • 24 Jan 2017 Results (n=15983) assessing risk factors of developing severe renal tubulopathy in patients treated with tenofovir disoproxil fumarate, published in the Journal of Infection
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top